EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trentin, P. G.
Right arrow Articles by Rae, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trentin, P. G.
Right arrow Articles by Rae, G. A.
Experimental Biology and Medicine 231:1146-1151 (2006)
© 2006 Society for Experimental Biology and Medicine


PAIN

Endothelin-1 Causes Pruritus in Mice

Patrícia Gonçalves Trentin*, Marcília Baticy Fernandes*, Pedro D’Orléans-Juste{dagger} and Giles Alexander Rae*,1

* Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil; and {dagger} Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, Sherbrooke, Canada

To whom requests for reprints should be addressed at 1 Universidade Federal de Santa Catarina, Center of Biological Sciences, Block D, Trindade, Florianópolis, SC 88040–900, Brazil. E-mail: garae{at}farmaco.ufsc.br

Abstract

Endothelin (ET)-1 evokes a burning pruritus sensation when injected intradermally in humans and nocifensive behavior when injected into the hind paw of rodents. Because pain and pruritus are clearly distinct nociceptive sensory modalities in humans, the current study evaluates the potential of ET-1 to elicit scratching behavior in mice. Mice received an intradermal injection of 1–30 pmol ET-1; 10 µg of the mast cell degranulator compound, 48/80; 100 nmol histamine; or vehicle into the scruff, and the number of scratching bouts displayed during the first 40 mins was recorded. ET-1 caused dose-dependent scratching bouts, which, like the responses to histamine and compound 48/80, occurred mainly during the first 5 to 10 mins of injection, but fewer episodes were also seen up to 35 mins. The effect of ET-1 was maximal at 10 pmol (total 40 ± 7 bouts), a value similar to that caused by histamine (52 ± 5 bouts) and compound 48/80 (53 ± 6 bouts). The selective ETB receptor agonist, IRL-1620 (10 pmol), was not pruritic per se, and actually inhibited responses to histamine and ET-1. Pruritus induced by ET-1 was inhibited by the ETA receptor antagonists, 10 nmol BQ-123 (co-injected; net inhibition, 87%) and 10 mg/kg atrasentan (intraperitoneal administration; net inhibition, 83%), or the ETB receptor antagonist, 20 mg/kg A-192621 (intraperitoneal administration; net inhibition, 64%), but the response was augmented by co-injection of the ETB receptor antagonist, 3 nmol BQ-788 (net potentiation, 234%). Responses to compound 48/80 or responsiveness of vehicle-treated mice were unaffected by these antagonists. Thus, ET-1 displays potent pruritic actions in the mouse mediated to a substantial extent via local ETA receptors. The findings with IRL-1620 and BQ-788 suggest that local ETB receptors exert an antipruritic role, but, for reasons still unknown, the results obtained using systemic A-192621 injection are at variance with this view.

Key Words: pruritus • endothelin-1 • histamine • compound 48/80 • scratching behavior • mice







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Experimental Biology and Medicine.